Parenteral Drugs (India) Ltd.

As of March 31, 2022, Parenteral Drugs (India) Ltd. has 29.82M shares outstanding.

These figures are as of March 31, 2022. The price-to-sales ratio is 1.26, and the price-to-book ratio stands at -0.01.

These figures are as of March 31, 2022. The EV/Sales ratio of 13.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Parenteral Drugs (India) Ltd. trades at an EV/FCF ratio of 1.59, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of March 31, 2022, Parenteral Drugs (India) Ltd. maintains a current ratio of 0.06, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -13.01, indicating conservative leverage, while an interest coverage ratio of -0.52 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2022, Parenteral Drugs (India) Ltd. posted a negative return on equity (ROE) of -407.39, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -14.51, reflecting losses generated across the asset base. Inventory turnover of 4.17 indicates how many times Parenteral Drugs (India) Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2022, Parenteral Drugs (India) Ltd. posted a gross margin of 35.67, reflecting its pricing power and cost economics. The operating margin of -649.25 and net profit margin of -898.77 provide insight into operational efficiency.

Parenteral Drugs (India) Ltd.'s most recent stock split took place on September 13, 2010 with a 100000:133333 split ratio.

As of March 31, 2022, Parenteral Drugs (India) Ltd. has an Altman Z-Score of -3.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.